{"id":2407,"date":"2023-11-24T10:36:06","date_gmt":"2023-11-24T09:36:06","guid":{"rendered":"https:\/\/semmelweis.hu\/esk\/?p=2407"},"modified":"2026-01-08T10:37:01","modified_gmt":"2026-01-08T09:37:01","slug":"a-covid-19-elleni-vedooltasok-eredmenyessege-a-korhazi-ellatast-igenylo-megbetegedesekkel-szemben-a-felnottek-koreben-az-omikron-varians-dominanciajanak-idoszakaban","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/esk\/2023\/11\/24\/a-covid-19-elleni-vedooltasok-eredmenyessege-a-korhazi-ellatast-igenylo-megbetegedesekkel-szemben-a-felnottek-koreben-az-omikron-varians-dominanciajanak-idoszakaban\/","title":{"rendered":"A COVID-19 elleni v\u00e9d\u0151olt\u00e1sok eredm\u00e9nyess\u00e9ge a k\u00f3rh\u00e1zi ell\u00e1t\u00e1st ig\u00e9nyl\u0151 megbeteged\u00e9sekkel szemben a feln\u0151ttek k\u00f6r\u00e9ben az Omikron vari\u00e1ns dominanci\u00e1j\u00e1nak id\u0151szak\u00e1ban"},"content":{"rendered":"<h3 style=\"text-align: center\"><strong>Az I-MOVE*-COVID-19 \u00e9s a VEBIS** SARI VE eur\u00f3pai k\u00f3rh\u00e1zi vizsg\u00e1latok eredm\u00e9nye, 2021. december \u2013 2022. j\u00falius<\/strong><\/h3>\n<p style=\"text-align: justify\">Az I-MOVE-COVID-19 \u00e9s a VEBIS k\u00f3rh\u00e1zi h\u00e1l\u00f3zatok \u2013 k\u00f6zt\u00fck Magyarorsz\u00e1g r\u00e9szv\u00e9tel\u00e9vel \u2013 2021. eleje \u00f3ta m\u00e9rik a Covid-19 elleni v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9get (VE) Eur\u00f3pa t\u00f6bb orsz\u00e1g\u00e1ban. Jelen vizsg\u00e1latunkban azt \u00e9rt\u00e9kelt\u00fck, hogy az olt\u00e1sok milyen m\u00e9rt\u00e9kben el\u0151zt\u00e9k meg a k\u00f3rh\u00e1zi kezel\u00e9st ig\u00e9nyl\u0151 megbeteged\u00e9seket a BA.1, BA.2, BA.4\/5 Omikron alvari\u00e1nsok dominanci\u00e1j\u00e1nak id\u0151szak\u00e1ban az eur\u00f3pai feln\u0151tt lakoss\u00e1g k\u00f6r\u00e9ben.<\/p>\n<p style=\"text-align: justify\">A VE becsl\u00e9seket 13 eur\u00f3pai orsz\u00e1g 46 k\u00f3rh\u00e1z\u00e1val k\u00f6z\u00f6sen v\u00e9gezt\u00fck 2021. december \u00e9s 2022. j\u00falius k\u00f6z\u00f6tt. A vizsg\u00e1lat elrendez\u00e9se teszt-negat\u00edv, eset-kontroll m\u00f3dszertan szerint t\u00f6rt\u00e9nt. A s\u00falyos akut l\u00e9g\u00fati megbeteged\u00e9ssel (SARI) k\u00f3rh\u00e1zi ell\u00e1t\u00e1sra szorul\u00f3 20 \u00e9ves \u00e9s id\u0151sebb betegeket hasonl\u00edtottuk \u00f6ssze annak alapj\u00e1n, hogy a RT-PCR laborat\u00f3riumi tesztj\u00fck igazolt-e n\u00e1luk SARS-CoV-2 fert\u0151z\u00e9st. Ennek megfelel\u0151en azok, akikn\u00e9l a vizsg\u00e1lat eredm\u00e9nye pozit\u00edv lett (2779 f\u0151), az esetek csoportj\u00e1ba ker\u00fcltek, m\u00edg a negat\u00edv eredm\u00e9nnyel rendelkez\u0151 p\u00e1ciensek (2362 f\u0151 a kontrollok csoportj\u00e1ba ker\u00fcltek. Az abszol\u00fat VE-t az oltott \u00e9s oltatlan p\u00e1ciensekn\u00e9l k\u00fcl\u00f6n becs\u00fclt\u00fck.<\/p>\n<p style=\"text-align: justify\">Oltottnak azokat a betegeket tekintett\u00fck, akik a teljes els\u0151dleges olt\u00e1si sorozatban (alapimmuniz\u00e1l\u00e1s) r\u00e9szes\u00fcltek. Ezen a csoporton bel\u00fcl az al\u00e1bbi alcsoportokat k\u00fcl\u00f6nb\u00f6ztett\u00fck meg:<\/p>\n<ul style=\"text-align: justify\">\n<li>azokat, akik m\u00e9g nem kaptak eml\u00e9keztet\u0151 (booster) olt\u00e1st, \u00e9s az els\u0151dleges olt\u00e1si sor utols\u00f3 d\u00f3zis\u00e1nak bead\u00e1sa kevesebb mint 150 (&lt;150) nappal a t\u00fcnetek megjelen\u00e9se el\u0151tt t\u00f6rt\u00e9nt (1-2. elemz\u00e9s);<\/li>\n<li>valamint azokat, akik r\u00e9szes\u00fcltek booster olt\u00e1sban, az els\u0151dleges olt\u00e1si sor utols\u00f3 d\u00f3zis\u00e1nak bead\u00e1sa legal\u00e1bb 150 (\u2265150) nappal a t\u00fcnetek megjelen\u00e9se el\u0151tt t\u00f6rt\u00e9nt (3-5. elemz\u00e9s).<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Eredm\u00e9nyeinket olt\u00f3anyagok szerint \u00f6sszes\u00edtve, korcsoport szerint, valamint az olt\u00e1s \u00f3ta eltelt id\u0151 f\u00fcggv\u00e9ny\u00e9ben sz\u00e1m\u00edtottuk \u00e9s korrig\u00e1ltuk a mintav\u00e9tel d\u00e1tum\u00e1ra, \u00e9letkorra, nemre \u00e9s kr\u00f3nikus megbeteged\u00e9s(ek) jelenl\u00e9t\u00e9re.<\/p>\n<p style=\"text-align: justify\">Az alapimmuniz\u00e1l\u00e1st k\u00f6vet\u0151en a t\u00fcnetek megjelen\u00e9s\u00e9ig sz\u00e1m\u00edtott &lt;150 napos id\u0151szakban a k\u00f3rh\u00e1zi kezel\u00e9st ig\u00e9nyl\u0151 Covid-19 elleni VE 51% volt. Azokn\u00e1l, akikn\u00e9l a t\u00fcnetek \u2265150 nappal az utols\u00f3 d\u00f3zis bead\u00e1s\u00e1t k\u00f6vet\u0151en jelentkeztek, az els\u0151dleges olt\u00e1si sorozat 43%-os v\u00e9detts\u00e9get ny\u00fajtott, m\u00edg az eml\u00e9keztet\u0151 d\u00f3zisban r\u00e9szes\u00fcl\u0151kn\u00e9l, enn\u00e9l is magasabb, 59%-os VE-t becs\u00fclt\u00fcnk.<\/p>\n<p style=\"text-align: justify\">Az eml\u00e9keztet\u0151 d\u00f3zis \u00e1ltal kiv\u00e1ltott v\u00e9delem k\u00fcl\u00f6n\u00f6sen magasnak bizonyult az els\u0151 h\u00f3napokban: az eml\u00e9keztet\u0151 d\u00f3zist k\u00f6vet\u0151 14-59 nap k\u00f6z\u00f6tt 85%, m\u00edg 120-179 nap eltelt\u00e9vel is 36% VE volt kimutathat\u00f3. Az els\u0151 eml\u00e9keztet\u0151 olt\u00e1s az \u00f6sszes vizsg\u00e1lt korcsoportban (20-59, 60-79 \u00e9s \u226580 \u00e9v) legal\u00e1bb 81%-os v\u00e9delmet biztos\u00edtott az olt\u00e1st k\u00f6vet\u0151 els\u0151 k\u00e9t h\u00f3napban.<\/p>\n<p style=\"text-align: justify\">Eredm\u00e9nyeink azt mutatj\u00e1k, hogy az Omikron-vari\u00e1ns dominanci\u00e1ja idej\u00e9n a COVID-19 olt\u00e1sok \u2013 k\u00fcl\u00f6n\u00f6sen az eml\u00e9keztet\u0151 d\u00f3zis \u2013 tov\u00e1bbra is jelent\u0151s v\u00e9delmet ny\u00fajtottak a s\u00falyos, k\u00f3rh\u00e1zi kezel\u00e9st ig\u00e9nyl\u0151 megbeteged\u00e9sekkel szemben. A vakcin\u00e1k \u00e1ltal biztos\u00edtott v\u00e9detts\u00e9g az id\u0151 el\u0151rehaladt\u00e1val cs\u00f6kken, ugyanakkor az eml\u00e9keztet\u0151 olt\u00e1sok jelent\u0151sen n\u00f6velik a v\u00e9detts\u00e9get, k\u00fcl\u00f6n\u00f6sen az olt\u00e1st k\u00f6vet\u0151 els\u0151 h\u00f3napokban.<\/p>\n<ol style=\"text-align: justify\">\n<li><span style=\"font-size: 12pt\"><strong>\u00e1bra: SARI-betegek sz\u00e1ma eseti st\u00e1tusz \u00e9s Covid-19 elleni olt\u00e1s bead\u00e1s\u00e1nak hete vagy mintav\u00e9tel hete szerint (teljes alapimmuniz\u00e1l\u00e1s \u00e9s eml\u00e9keztet\u0151 olt\u00e1sok), olt\u00f3anyagonk\u00e9nt, I-MOVE-COVID-19 \u00e9s VEBIS k\u00f3rh\u00e1zi v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9gi vizsg\u00e1latok, Eur\u00f3pa, 2021\u20132022 (n = 5 141)<\/strong><\/span><\/li>\n<\/ol>\n<p style=\"text-align: justify\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-2408 size-full\" src=\"https:\/\/semmelweis.hu\/esk\/files\/2026\/01\/Recenzio23.png\" alt=\"\" width=\"1225\" height=\"630\" srcset=\"https:\/\/semmelweis.hu\/esk\/files\/2026\/01\/Recenzio23.png 1225w, https:\/\/semmelweis.hu\/esk\/files\/2026\/01\/Recenzio23-400x206.png 400w, https:\/\/semmelweis.hu\/esk\/files\/2026\/01\/Recenzio23-1024x527.png 1024w, https:\/\/semmelweis.hu\/esk\/files\/2026\/01\/Recenzio23-768x395.png 768w, https:\/\/semmelweis.hu\/esk\/files\/2026\/01\/Recenzio23-753x387.png 753w\" sizes=\"auto, (max-width: 1225px) 100vw, 1225px\" \/><\/p>\n<p style=\"text-align: justify\"><span style=\"font-size: 12pt\">I-MOVE: Influenza \u2013 Monitoring Vaccine Effectiveness in Europe; SARI: s\u00falyos akut l\u00e9g\u00fati megbeteged\u00e9s; SARS-CoV-2: s\u00falyos akut l\u00e9gz\u0151szervi szindr\u00f3m\u00e1t okoz\u00f3 koronav\u00edrus-2; VEBIS: Vaccine Effectiveness, Burden and Impact Studies.<br \/>\n<\/span><span style=\"font-size: 12pt\">Forr\u00e1s: Euro Surveill. 2023 Nov 23;28(47):2300187. doi: 10.2807\/1560-7917.ES.2023.28.47.2300187 publik\u00e1ci\u00f3 3. \u00e1br\u00e1ja alapj\u00e1n SE ESK saj\u00e1t szerkeszt\u00e9s<\/p>\n<p><\/span><\/p>\n<h3 style=\"text-align: justify\"><strong>Vaccine effectiveness against COVID-19 hospitalisation in adults (\u2265 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022<\/strong><\/h3>\n<p style=\"text-align: justify\"><em>Angela Mc Rose <\/em>(Epiconcept, Paris, France)<br \/>\n<em>Nathalie Nicolay<\/em> (European Centre for Disease Prevention and Control, Stockholm, Sweden)<br \/>\n<em>Judit Krisztina Horv\u00e1th <\/em>(National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary)<br \/>\n<em>Mih\u00e1ly P\u00e1l Kunst\u00e1r<\/em> (National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary)<br \/>\nand the I-MOVE &amp; VEBIS Hospital study team<\/p>\n<h5 style=\"text-align: justify\"><strong>Abstract<\/strong><\/h5>\n<p style=\"text-align: justify\">Introduction:<\/p>\n<p style=\"text-align: justify\">The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021.<\/p>\n<p style=\"text-align: justify\">Aim:<\/p>\n<p style=\"text-align: justify\">We aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients \u2265 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period).<\/p>\n<p style=\"text-align: justify\">Methods:<\/p>\n<p style=\"text-align: justify\">In both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received \u2265 14 days before symptom onset (stratifying first booster into received &lt; 150 and \u2265 150 days after last PSV dose). We measured VE overall, by vaccine category\/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence\/absence of at least one commonly collected chronic condition.<\/p>\n<p style=\"text-align: justify\">Results:<\/p>\n<p style=\"text-align: justify\">We included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received \u2265 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively.<\/p>\n<p style=\"text-align: justify\">Conclusions:<\/p>\n<p style=\"text-align: justify\">Our results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset &lt; 120 days after first booster dose.<\/p>\n<p style=\"text-align: justify\"><span style=\"font-size: 12pt\">* Influenza \u2013 Monitoring Vaccine Effectiveness in Europe<\/span><\/p>\n<p style=\"text-align: justify\"><span style=\"font-size: 12pt\">** Vaccine Effectiveness, Burden and Impact Studies<\/span><\/p>\n<p style=\"text-align: justify\"><span style=\"font-size: 12pt\">Maurel M, Pozo F, P\u00e9rez-Gimeno G, Buda S, S\u00e8ve N, Oroszi B, Hooiveld M, Gomez V, Domegan L, Mart\u00ednez-Baz I, Ili\u0107 M, Carnahan AS, Mihai ME, Mart\u00ednez A, Goerlitz L, Enouf V, Horv\u00e1th JK, Dijkstra F, Rodrigues AP, Bennett C, Trobajo-Sanmart\u00edn C, Mlinari\u0107 I, Latorre-Margalef N, Ivanciuc A, Lopez A, D\u00fcrrwald R, Falchi A, T\u00fari G, Meijer A, Melo A, O&#8217;Donnell J, Castilla J, Vu\u010dina VV, Hagey TS, Lazar M, Kaczmarek M, Bacci S, Kissling E; VEBIS study team. Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study. Influenza Other Respir Viruses. 2024 Jan 10;18(1):e13243. doi: 10.1111\/irv.13243. PMID: 38204584; PMCID: PMC10777262.<\/span><\/p>\n<p style=\"text-align: justify\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37997665\/\" target=\"_blank\" rel=\"noopener\"><strong>https:\/\/pubmed.ncbi.nlm.nih.gov\/37997665\/<\/strong><\/a><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-size: 12pt;color: #003366\"><em>K\u00e9sz\u00edtette az <img loading=\"lazy\" decoding=\"async\" class=\"alignnone  wp-image-1068\" src=\"https:\/\/semmelweis.hu\/esk\/files\/2024\/02\/se_esk_logo_fekvo_sotet-400x90.png\" alt=\"\" width=\"263\" height=\"59\" srcset=\"https:\/\/semmelweis.hu\/esk\/files\/2024\/02\/se_esk_logo_fekvo_sotet-400x90.png 400w, https:\/\/semmelweis.hu\/esk\/files\/2024\/02\/se_esk_logo_fekvo_sotet-768x172.png 768w, https:\/\/semmelweis.hu\/esk\/files\/2024\/02\/se_esk_logo_fekvo_sotet-753x169.png 753w, https:\/\/semmelweis.hu\/esk\/files\/2024\/02\/se_esk_logo_fekvo_sotet.png 900w\" sizes=\"auto, (max-width: 263px) 100vw, 263px\" \/>\u00a0<\/em><\/span><\/p>\n<p><span style=\"font-size: 12pt\"><em><img loading=\"lazy\" decoding=\"async\" class=\"alignnone  wp-image-1662\" src=\"https:\/\/semmelweis.hu\/esk\/files\/2024\/10\/Nemzeti_Labor__logo-400x167.jpg\" alt=\"\" width=\"165\" height=\"69\" srcset=\"https:\/\/semmelweis.hu\/esk\/files\/2024\/10\/Nemzeti_Labor__logo-400x167.jpg 400w, https:\/\/semmelweis.hu\/esk\/files\/2024\/10\/Nemzeti_Labor__logo.jpg 710w\" sizes=\"auto, (max-width: 165px) 100vw, 165px\" \/><\/em><span style=\"color: #003366\">RRF-2.3.1-21-2022-00006\u00a0<\/span><\/span><\/p>\n<p><b><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-803 \" src=\"https:\/\/semmelweis.hu\/esk\/files\/2023\/11\/RRF-1024x118.jpg\" alt=\"\" width=\"788\" height=\"91\" srcset=\"https:\/\/semmelweis.hu\/esk\/files\/2023\/11\/RRF-1024x118.jpg 1024w, https:\/\/semmelweis.hu\/esk\/files\/2023\/11\/RRF-400x46.jpg 400w, https:\/\/semmelweis.hu\/esk\/files\/2023\/11\/RRF-768x88.jpg 768w, https:\/\/semmelweis.hu\/esk\/files\/2023\/11\/RRF-1536x177.jpg 1536w, https:\/\/semmelweis.hu\/esk\/files\/2023\/11\/RRF-2048x235.jpg 2048w, https:\/\/semmelweis.hu\/esk\/files\/2023\/11\/RRF-753x87.jpg 753w\" sizes=\"auto, (max-width: 788px) 100vw, 788px\" \/><\/b><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Az I-MOVE*-COVID-19 \u00e9s a VEBIS** SARI VE eur\u00f3pai k\u00f3rh\u00e1zi vizsg\u00e1latok eredm\u00e9nye, 2021. december \u2013 2022. j\u00falius Az I-MOVE-COVID-19 \u00e9s a VEBIS k\u00f3rh\u00e1zi h\u00e1l\u00f3zatok \u2013 k\u00f6zt\u00fck Magyarorsz\u00e1g r\u00e9szv\u00e9tel\u00e9vel \u2013 2021. eleje \u00f3ta m\u00e9rik a Covid-19 elleni v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9get (VE) Eur\u00f3pa t\u00f6bb orsz\u00e1g\u00e1ban. Jelen vizsg\u00e1latunkban azt \u00e9rt\u00e9kelt\u00fck, hogy az olt\u00e1sok milyen m\u00e9rt\u00e9kben el\u0151zt\u00e9k meg a k\u00f3rh\u00e1zi kezel\u00e9st ig\u00e9nyl\u0151 &hellip;<\/p>\n","protected":false},"author":102284,"featured_media":2408,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-2407","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cikk-osszefoglalok"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2407","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/users\/102284"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/comments?post=2407"}],"version-history":[{"count":3,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2407\/revisions"}],"predecessor-version":[{"id":2411,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2407\/revisions\/2411"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media\/2408"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media?parent=2407"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/categories?post=2407"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/tags?post=2407"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}